12,767 Becton, Dickinson and Company $BDX Shares Bought by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the third quarter, HoldingsChannel reports. The firm owned 95,867 shares of the medical instruments supplier’s stock after buying an additional 12,767 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Becton, Dickinson and Company were worth $17,160,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in BDX. Diversified Management Inc. purchased a new stake in Becton, Dickinson and Company during the 3rd quarter valued at approximately $2,831,000. GAMMA Investing LLC grew its stake in shares of Becton, Dickinson and Company by 64.8% in the 3rd quarter. GAMMA Investing LLC now owns 7,679 shares of the medical instruments supplier’s stock valued at $1,375,000 after purchasing an additional 3,019 shares during the last quarter. Dorato Capital Management increased its holdings in shares of Becton, Dickinson and Company by 4.6% in the third quarter. Dorato Capital Management now owns 2,902 shares of the medical instruments supplier’s stock valued at $523,000 after purchasing an additional 127 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 22.5% during the third quarter. Farther Finance Advisors LLC now owns 8,721 shares of the medical instruments supplier’s stock worth $1,561,000 after purchasing an additional 1,599 shares during the last quarter. Finally, CoreCap Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.6% during the third quarter. CoreCap Advisors LLC now owns 5,729 shares of the medical instruments supplier’s stock worth $1,025,000 after purchasing an additional 90 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of analyst reports. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Piper Sandler raised their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. Finally, Royal Bank Of Canada raised their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $185.07.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $183.69 on Friday. The company has a market cap of $50.61 billion, a P/E ratio of 55.33, a price-to-earnings-growth ratio of 12.32 and a beta of 0.21. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The business has a fifty day moving average of $182.33 and a two-hundred day moving average of $162.52. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the company posted $3.68 EPS. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were issued a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insider Activity

In other news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Feld sold 165 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 6,906 shares of company stock worth $1,265,855. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.